Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds BTIG Downgrades T2 Biosystems to Neutral

BTIG Downgrades T2 Biosystems to Neutral

BTIG analyst Mark Massaro downgrades T2 Biosystems (NASDAQ:TTOO) from Buy to Neutral.

byBenzinga Newsdesk

July 7, 2022

1 minute read

BTIG analyst Mark Massaro downgrades T2 Biosystems (NASDAQ:TTOO) from Buy to Neutral.

News

Miromatrix Receives New Patent for Its Novel Perfusion Decellularization and Recellularization Technology

By Benzinga Newsdesk

August 25, 7:22 AM

Miromatrix Medical Inc. (NASDAQ:MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, has received a new patent from the

MIRO

Mizuho Maintains Buy on Axalta Coating Sys, Lowers Price Target to $31

By Benzinga Newsdesk

July 14, 7:05 AM

Mizuho analyst Christopher Parkinson maintains Axalta Coating Sys (NYSE:AXTA) with a Buy and lowers the price target from $34 to $31.

AXTA

Keybanc Maintains Overweight on Marqeta, Raises Price Target to $12

By Benzinga Newsdesk

August 11, 4:38 AM

Keybanc analyst Josh Beck maintains Marqeta (NASDAQ:MQ) with a Overweight and raises the price target from $11 to $12.

Sports Betting Boon: DraftKings Set To Benefit From Growing Handle And Margin Expansion, Analyst Says

By Nabaparna Bhattacharya

April 10, 1:30 PM

Needham analyst Bernie McTernan reiterated a Buy rating on the shares of DraftKings Inc. (NASDAQ:DKNG) with a price target of $28. The…

DKNG

BTIG Downgrades T2 Biosystems to Neutral

Related Posts

Miromatrix Receives New Patent for Its Novel Perfusion Decellularization and Recellularization Technology

Mizuho Maintains Buy on Axalta Coating Sys, Lowers Price Target to $31

Keybanc Maintains Overweight on Marqeta, Raises Price Target to $12

Sports Betting Boon: DraftKings Set To Benefit From Growing Handle And Margin Expansion, Analyst Says